nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—SLCO1B1—Cabazitaxel—prostate cancer	0.238	0.315	CbGbCtD
Penicillamine—SLCO1B1—Estrone—prostate cancer	0.233	0.308	CbGbCtD
Penicillamine—SLCO1B1—Conjugated Estrogens—prostate cancer	0.152	0.201	CbGbCtD
Penicillamine—SLCO1B1—Estradiol—prostate cancer	0.134	0.177	CbGbCtD
Penicillamine—L-Cysteine—CSAD—prostate cancer	0.00444	1	CrCbGaD
Penicillamine—SLCO1B1—Irinotecan Pathway—CYP3A5—prostate cancer	0.0011	0.0768	CbGpPWpGaD
Penicillamine—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—prostate cancer	0.000891	0.062	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—AMACR—prostate cancer	0.000777	0.0541	CbGpPWpGaD
Penicillamine—SLCO1B1—Drug Induction of Bile Acid Pathway—SULT2A1—prostate cancer	0.000692	0.0481	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—CYP7B1—prostate cancer	0.000604	0.042	CbGpPWpGaD
Penicillamine—SLCO1B1—Recycling of bile acids and salts—NCOA2—prostate cancer	0.00057	0.0396	CbGpPWpGaD
Penicillamine—SLCO1B1—Irinotecan Pathway—CYP3A4—prostate cancer	0.00057	0.0396	CbGpPWpGaD
Penicillamine—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—prostate cancer	0.000488	0.0339	CbGpPWpGaD
Penicillamine—SLCO1B1—Recycling of bile acids and salts—NCOA1—prostate cancer	0.00048	0.0334	CbGpPWpGaD
Penicillamine—SLCO1B1—Recycling of bile acids and salts—RXRA—prostate cancer	0.000457	0.0318	CbGpPWpGaD
Penicillamine—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000394	0.0274	CbGpPWpGaD
Penicillamine—SLCO1B1—Irinotecan Pathway—APC—prostate cancer	0.000332	0.0231	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—AKR1C3—prostate cancer	0.000317	0.0221	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—NCOA2—prostate cancer	0.000298	0.0207	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—NCOA1—prostate cancer	0.000251	0.0175	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—RXRA—prostate cancer	0.000239	0.0166	CbGpPWpGaD
Penicillamine—Lymphadenopathy—Epirubicin—prostate cancer	0.000212	0.000947	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000212	0.000947	CcSEcCtD
Penicillamine—Leukopenia—Mitoxantrone—prostate cancer	0.00021	0.000934	CcSEcCtD
Penicillamine—Thrombophlebitis—Epirubicin—prostate cancer	0.000209	0.000934	CcSEcCtD
Penicillamine—Mouth ulceration—Doxorubicin—prostate cancer	0.000209	0.000932	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Epirubicin—prostate cancer	0.000208	0.000929	CcSEcCtD
Penicillamine—Hepatic function abnormal—Epirubicin—prostate cancer	0.000207	0.000925	CcSEcCtD
Penicillamine—Urticaria—Goserelin—prostate cancer	0.000205	0.000916	CcSEcCtD
Penicillamine—Body temperature increased—Goserelin—prostate cancer	0.000204	0.000912	CcSEcCtD
Penicillamine—Muscular weakness—Prednisone—prostate cancer	0.000204	0.000912	CcSEcCtD
Penicillamine—Renal failure—Docetaxel—prostate cancer	0.000204	0.000908	CcSEcCtD
Penicillamine—Urticaria—Conjugated Estrogens—prostate cancer	0.000204	0.000908	CcSEcCtD
Penicillamine—Neuropathy peripheral—Docetaxel—prostate cancer	0.000203	0.000905	CcSEcCtD
Penicillamine—Angiopathy—Etoposide—prostate cancer	0.000203	0.000905	CcSEcCtD
Penicillamine—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000203	0.000903	CcSEcCtD
Penicillamine—Stomatitis—Docetaxel—prostate cancer	0.000202	0.0009	CcSEcCtD
Penicillamine—Hepatic failure—Epirubicin—prostate cancer	0.000202	0.000899	CcSEcCtD
Penicillamine—Vomiting—Ethinyl Estradiol—prostate cancer	0.0002	0.000891	CcSEcCtD
Penicillamine—Arthralgia—Mitoxantrone—prostate cancer	0.000199	0.000889	CcSEcCtD
Penicillamine—Skin disorder—Estradiol—prostate cancer	0.000199	0.000888	CcSEcCtD
Penicillamine—Anxiety—Mitoxantrone—prostate cancer	0.000199	0.000886	CcSEcCtD
Penicillamine—Rash—Ethinyl Estradiol—prostate cancer	0.000198	0.000884	CcSEcCtD
Penicillamine—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000198	0.000883	CcSEcCtD
Penicillamine—Alopecia—Etoposide—prostate cancer	0.000198	0.000881	CcSEcCtD
Penicillamine—Renal failure—Capecitabine—prostate cancer	0.000197	0.000879	CcSEcCtD
Penicillamine—Lymphadenopathy—Doxorubicin—prostate cancer	0.000197	0.000877	CcSEcCtD
Penicillamine—Neuropathy peripheral—Capecitabine—prostate cancer	0.000197	0.000876	CcSEcCtD
Penicillamine—Pancreatitis—Prednisone—prostate cancer	0.000196	0.000876	CcSEcCtD
Penicillamine—Hepatobiliary disease—Docetaxel—prostate cancer	0.000196	0.000873	CcSEcCtD
Penicillamine—Stomatitis—Capecitabine—prostate cancer	0.000195	0.000872	CcSEcCtD
Penicillamine—Thrombophlebitis—Doxorubicin—prostate cancer	0.000194	0.000864	CcSEcCtD
Penicillamine—Agranulocytosis—Docetaxel—prostate cancer	0.000193	0.000862	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000193	0.0134	CbGpPWpGaD
Penicillamine—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.000193	0.00086	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Epirubicin—prostate cancer	0.000192	0.000857	CcSEcCtD
Penicillamine—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000192	0.000856	CcSEcCtD
Penicillamine—Haematuria—Capecitabine—prostate cancer	0.000191	0.000853	CcSEcCtD
Penicillamine—Dysgeusia—Etoposide—prostate cancer	0.000191	0.00085	CcSEcCtD
Penicillamine—Hypersensitivity—Goserelin—prostate cancer	0.000191	0.00085	CcSEcCtD
Penicillamine—Hepatobiliary disease—Capecitabine—prostate cancer	0.00019	0.000846	CcSEcCtD
Penicillamine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000189	0.000842	CcSEcCtD
Penicillamine—Agranulocytosis—Capecitabine—prostate cancer	0.000187	0.000834	CcSEcCtD
Penicillamine—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000187	0.000834	CcSEcCtD
Penicillamine—Haemoglobin—Docetaxel—prostate cancer	0.000187	0.000833	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000187	0.000833	CcSEcCtD
Penicillamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000187	0.000833	CcSEcCtD
Penicillamine—Hepatic failure—Doxorubicin—prostate cancer	0.000187	0.000832	CcSEcCtD
Penicillamine—Haemorrhage—Docetaxel—prostate cancer	0.000186	0.000829	CcSEcCtD
Penicillamine—Hypoglycaemia—Epirubicin—prostate cancer	0.000186	0.000828	CcSEcCtD
Penicillamine—Skin disorder—Mitoxantrone—prostate cancer	0.000186	0.000828	CcSEcCtD
Penicillamine—Urinary tract disorder—Docetaxel—prostate cancer	0.000184	0.000819	CcSEcCtD
Penicillamine—Urethral disorder—Docetaxel—prostate cancer	0.000182	0.000813	CcSEcCtD
Penicillamine—Anorexia—Mitoxantrone—prostate cancer	0.000182	0.000812	CcSEcCtD
Penicillamine—Haemoglobin—Capecitabine—prostate cancer	0.000181	0.000807	CcSEcCtD
Penicillamine—Haemorrhage—Capecitabine—prostate cancer	0.00018	0.000803	CcSEcCtD
Penicillamine—Anaemia—Etoposide—prostate cancer	0.00018	0.000803	CcSEcCtD
Penicillamine—Decreased appetite—Estradiol—prostate cancer	0.000178	0.000795	CcSEcCtD
Penicillamine—Urinary tract disorder—Capecitabine—prostate cancer	0.000178	0.000793	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Doxorubicin—prostate cancer	0.000178	0.000793	CcSEcCtD
Penicillamine—Diarrhoea—Goserelin—prostate cancer	0.000177	0.000789	CcSEcCtD
Penicillamine—Urethral disorder—Capecitabine—prostate cancer	0.000176	0.000787	CcSEcCtD
Penicillamine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000175	0.000782	CcSEcCtD
Penicillamine—Neuropathy peripheral—Prednisone—prostate cancer	0.000175	0.000781	CcSEcCtD
Penicillamine—Leukopenia—Etoposide—prostate cancer	0.000174	0.000777	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000174	0.000776	CcSEcCtD
Penicillamine—Hypoglycaemia—Doxorubicin—prostate cancer	0.000172	0.000766	CcSEcCtD
Penicillamine—Angiopathy—Docetaxel—prostate cancer	0.000169	0.000752	CcSEcCtD
Penicillamine—Tinnitus—Capecitabine—prostate cancer	0.000168	0.000748	CcSEcCtD
Penicillamine—Decreased appetite—Mitoxantrone—prostate cancer	0.000166	0.000741	CcSEcCtD
Penicillamine—Abdominal pain upper—Epirubicin—prostate cancer	0.000166	0.000738	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000165	0.000734	CcSEcCtD
Penicillamine—Vomiting—Goserelin—prostate cancer	0.000164	0.000733	CcSEcCtD
Penicillamine—Alopecia—Docetaxel—prostate cancer	0.000164	0.000733	CcSEcCtD
Penicillamine—Angiopathy—Capecitabine—prostate cancer	0.000163	0.000728	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000163	0.000728	CcSEcCtD
Penicillamine—Rash—Goserelin—prostate cancer	0.000163	0.000727	CcSEcCtD
Penicillamine—Dermatitis—Goserelin—prostate cancer	0.000163	0.000727	CcSEcCtD
Penicillamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000163	0.000726	CcSEcCtD
Penicillamine—Urticaria—Estradiol—prostate cancer	0.000163	0.000726	CcSEcCtD
Penicillamine—Mental disorder—Docetaxel—prostate cancer	0.000163	0.000726	CcSEcCtD
Penicillamine—Body temperature increased—Estradiol—prostate cancer	0.000162	0.000723	CcSEcCtD
Penicillamine—Rash—Conjugated Estrogens—prostate cancer	0.000162	0.00072	CcSEcCtD
Penicillamine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000161	0.00072	CcSEcCtD
Penicillamine—Haemoglobin—Prednisone—prostate cancer	0.000161	0.000719	CcSEcCtD
Penicillamine—Haemorrhage—Prednisone—prostate cancer	0.00016	0.000715	CcSEcCtD
Penicillamine—Muscular weakness—Epirubicin—prostate cancer	0.00016	0.000713	CcSEcCtD
Penicillamine—Alopecia—Capecitabine—prostate cancer	0.000159	0.000709	CcSEcCtD
Penicillamine—Dysgeusia—Docetaxel—prostate cancer	0.000158	0.000707	CcSEcCtD
Penicillamine—Mental disorder—Capecitabine—prostate cancer	0.000158	0.000703	CcSEcCtD
Penicillamine—Asthma—Epirubicin—prostate cancer	0.000157	0.000699	CcSEcCtD
Penicillamine—Thrombocytopenia—Etoposide—prostate cancer	0.000156	0.000694	CcSEcCtD
Penicillamine—Eosinophilia—Epirubicin—prostate cancer	0.000155	0.000692	CcSEcCtD
Penicillamine—Skin disorder—Etoposide—prostate cancer	0.000154	0.000688	CcSEcCtD
Penicillamine—Nausea—Goserelin—prostate cancer	0.000154	0.000685	CcSEcCtD
Penicillamine—Pancreatitis—Epirubicin—prostate cancer	0.000154	0.000685	CcSEcCtD
Penicillamine—Dysgeusia—Capecitabine—prostate cancer	0.000153	0.000684	CcSEcCtD
Penicillamine—Abdominal pain upper—Doxorubicin—prostate cancer	0.000153	0.000683	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000152	0.0106	CbGpPWpGaD
Penicillamine—Nausea—Conjugated Estrogens—prostate cancer	0.000152	0.000679	CcSEcCtD
Penicillamine—Urticaria—Mitoxantrone—prostate cancer	0.000152	0.000677	CcSEcCtD
Penicillamine—Anorexia—Etoposide—prostate cancer	0.000151	0.000676	CcSEcCtD
Penicillamine—Hypersensitivity—Estradiol—prostate cancer	0.000151	0.000674	CcSEcCtD
Penicillamine—Body temperature increased—Mitoxantrone—prostate cancer	0.000151	0.000674	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000151	0.000673	CcSEcCtD
Penicillamine—Anaemia—Docetaxel—prostate cancer	0.00015	0.000667	CcSEcCtD
Penicillamine—Pancytopenia—Epirubicin—prostate cancer	0.000149	0.000663	CcSEcCtD
Penicillamine—Muscular weakness—Doxorubicin—prostate cancer	0.000148	0.00066	CcSEcCtD
Penicillamine—Angiopathy—Prednisone—prostate cancer	0.000145	0.000649	CcSEcCtD
Penicillamine—Asthma—Doxorubicin—prostate cancer	0.000145	0.000646	CcSEcCtD
Penicillamine—Leukopenia—Docetaxel—prostate cancer	0.000145	0.000646	CcSEcCtD
Penicillamine—Anaemia—Capecitabine—prostate cancer	0.000145	0.000646	CcSEcCtD
Penicillamine—Eosinophilia—Doxorubicin—prostate cancer	0.000144	0.00064	CcSEcCtD
Penicillamine—Pancreatitis—Doxorubicin—prostate cancer	0.000142	0.000634	CcSEcCtD
Penicillamine—Alopecia—Prednisone—prostate cancer	0.000142	0.000632	CcSEcCtD
Penicillamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000141	0.000628	CcSEcCtD
Penicillamine—Mental disorder—Prednisone—prostate cancer	0.00014	0.000626	CcSEcCtD
Penicillamine—Diarrhoea—Estradiol—prostate cancer	0.00014	0.000626	CcSEcCtD
Penicillamine—Leukopenia—Capecitabine—prostate cancer	0.00014	0.000625	CcSEcCtD
Penicillamine—Decreased appetite—Etoposide—prostate cancer	0.000138	0.000616	CcSEcCtD
Penicillamine—Arthralgia—Docetaxel—prostate cancer	0.000138	0.000614	CcSEcCtD
Penicillamine—Pancytopenia—Doxorubicin—prostate cancer	0.000138	0.000614	CcSEcCtD
Penicillamine—Renal failure—Epirubicin—prostate cancer	0.000137	0.000612	CcSEcCtD
Penicillamine—Neuropathy peripheral—Epirubicin—prostate cancer	0.000137	0.000611	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000137	0.00061	CcSEcCtD
Penicillamine—Stomatitis—Epirubicin—prostate cancer	0.000136	0.000607	CcSEcCtD
Penicillamine—Arthralgia—Capecitabine—prostate cancer	0.000133	0.000595	CcSEcCtD
Penicillamine—Haematuria—Epirubicin—prostate cancer	0.000133	0.000594	CcSEcCtD
Penicillamine—Anxiety—Capecitabine—prostate cancer	0.000133	0.000593	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000132	0.000591	CcSEcCtD
Penicillamine—Hepatobiliary disease—Epirubicin—prostate cancer	0.000132	0.000589	CcSEcCtD
Penicillamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000131	0.000583	CcSEcCtD
Penicillamine—Vomiting—Estradiol—prostate cancer	0.00013	0.000581	CcSEcCtD
Penicillamine—Agranulocytosis—Epirubicin—prostate cancer	0.00013	0.000581	CcSEcCtD
Penicillamine—Thrombocytopenia—Docetaxel—prostate cancer	0.000129	0.000577	CcSEcCtD
Penicillamine—Rash—Estradiol—prostate cancer	0.000129	0.000577	CcSEcCtD
Penicillamine—Dermatitis—Estradiol—prostate cancer	0.000129	0.000576	CcSEcCtD
Penicillamine—Anaemia—Prednisone—prostate cancer	0.000129	0.000575	CcSEcCtD
Penicillamine—Skin disorder—Docetaxel—prostate cancer	0.000128	0.000572	CcSEcCtD
Penicillamine—Agitation—Prednisone—prostate cancer	0.000128	0.000572	CcSEcCtD
Penicillamine—Renal failure—Doxorubicin—prostate cancer	0.000127	0.000567	CcSEcCtD
Penicillamine—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000127	0.000565	CcSEcCtD
Penicillamine—Urticaria—Etoposide—prostate cancer	0.000126	0.000563	CcSEcCtD
Penicillamine—Haemoglobin—Epirubicin—prostate cancer	0.000126	0.000562	CcSEcCtD
Penicillamine—Stomatitis—Doxorubicin—prostate cancer	0.000126	0.000562	CcSEcCtD
Penicillamine—Anorexia—Docetaxel—prostate cancer	0.000126	0.000561	CcSEcCtD
Penicillamine—Body temperature increased—Etoposide—prostate cancer	0.000126	0.00056	CcSEcCtD
Penicillamine—Haemorrhage—Epirubicin—prostate cancer	0.000125	0.000559	CcSEcCtD
Penicillamine—Thrombocytopenia—Capecitabine—prostate cancer	0.000125	0.000558	CcSEcCtD
Penicillamine—Skin disorder—Capecitabine—prostate cancer	0.000124	0.000554	CcSEcCtD
Penicillamine—Urinary tract disorder—Epirubicin—prostate cancer	0.000124	0.000552	CcSEcCtD
Penicillamine—Haematuria—Doxorubicin—prostate cancer	0.000123	0.00055	CcSEcCtD
Penicillamine—Urethral disorder—Epirubicin—prostate cancer	0.000123	0.000548	CcSEcCtD
Penicillamine—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000122	0.000545	CcSEcCtD
Penicillamine—Anorexia—Capecitabine—prostate cancer	0.000122	0.000544	CcSEcCtD
Penicillamine—Nausea—Estradiol—prostate cancer	0.000122	0.000543	CcSEcCtD
Penicillamine—Vomiting—Mitoxantrone—prostate cancer	0.000121	0.000542	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000121	0.00842	CbGpPWpGaD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000121	0.00842	CbGpPWpGaD
Penicillamine—Agranulocytosis—Doxorubicin—prostate cancer	0.000121	0.000538	CcSEcCtD
Penicillamine—Rash—Mitoxantrone—prostate cancer	0.00012	0.000537	CcSEcCtD
Penicillamine—Dermatitis—Mitoxantrone—prostate cancer	0.00012	0.000537	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.00012	0.000537	CcSEcCtD
Penicillamine—Arthralgia—Prednisone—prostate cancer	0.000119	0.00053	CcSEcCtD
Penicillamine—Anxiety—Prednisone—prostate cancer	0.000118	0.000528	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000118	0.000526	CcSEcCtD
Penicillamine—Hypersensitivity—Etoposide—prostate cancer	0.000117	0.000522	CcSEcCtD
Penicillamine—Tinnitus—Epirubicin—prostate cancer	0.000117	0.000521	CcSEcCtD
Penicillamine—Haemoglobin—Doxorubicin—prostate cancer	0.000117	0.00052	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000116	0.00052	CcSEcCtD
Penicillamine—Haemorrhage—Doxorubicin—prostate cancer	0.000116	0.000517	CcSEcCtD
Penicillamine—Decreased appetite—Docetaxel—prostate cancer	0.000115	0.000512	CcSEcCtD
Penicillamine—Urinary tract disorder—Doxorubicin—prostate cancer	0.000115	0.000511	CcSEcCtD
Penicillamine—Angiopathy—Epirubicin—prostate cancer	0.000114	0.000507	CcSEcCtD
Penicillamine—Urethral disorder—Doxorubicin—prostate cancer	0.000114	0.000507	CcSEcCtD
Penicillamine—Nausea—Mitoxantrone—prostate cancer	0.000113	0.000506	CcSEcCtD
Penicillamine—Decreased appetite—Capecitabine—prostate cancer	0.000111	0.000496	CcSEcCtD
Penicillamine—Alopecia—Epirubicin—prostate cancer	0.000111	0.000494	CcSEcCtD
Penicillamine—Skin disorder—Prednisone—prostate cancer	0.000111	0.000493	CcSEcCtD
Penicillamine—Mental disorder—Epirubicin—prostate cancer	0.00011	0.00049	CcSEcCtD
Penicillamine—Diarrhoea—Etoposide—prostate cancer	0.000109	0.000485	CcSEcCtD
Penicillamine—Anorexia—Prednisone—prostate cancer	0.000109	0.000484	CcSEcCtD
Penicillamine—Tinnitus—Doxorubicin—prostate cancer	0.000108	0.000482	CcSEcCtD
Penicillamine—Dysgeusia—Epirubicin—prostate cancer	0.000107	0.000477	CcSEcCtD
Penicillamine—Angiopathy—Doxorubicin—prostate cancer	0.000105	0.000469	CcSEcCtD
Penicillamine—Body temperature increased—Docetaxel—prostate cancer	0.000104	0.000466	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000104	0.000463	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—GRHL1—prostate cancer	0.000103	0.00717	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CBR1—prostate cancer	0.000103	0.00717	CbGpPWpGaD
Penicillamine—Alopecia—Doxorubicin—prostate cancer	0.000103	0.000457	CcSEcCtD
Penicillamine—Mental disorder—Doxorubicin—prostate cancer	0.000102	0.000453	CcSEcCtD
Penicillamine—Urticaria—Capecitabine—prostate cancer	0.000102	0.000453	CcSEcCtD
Penicillamine—Body temperature increased—Capecitabine—prostate cancer	0.000101	0.000451	CcSEcCtD
Penicillamine—Vomiting—Etoposide—prostate cancer	0.000101	0.000451	CcSEcCtD
Penicillamine—Anaemia—Epirubicin—prostate cancer	0.000101	0.00045	CcSEcCtD
Penicillamine—Agitation—Epirubicin—prostate cancer	0.0001	0.000447	CcSEcCtD
Penicillamine—Rash—Etoposide—prostate cancer	0.0001	0.000447	CcSEcCtD
Penicillamine—Dermatitis—Etoposide—prostate cancer	0.0001	0.000446	CcSEcCtD
Penicillamine—Decreased appetite—Prednisone—prostate cancer	9.9e-05	0.000442	CcSEcCtD
Penicillamine—Dysgeusia—Doxorubicin—prostate cancer	9.89e-05	0.000441	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	9.82e-05	0.00683	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	9.8e-05	0.00682	CbGpPWpGaD
Penicillamine—Leukopenia—Epirubicin—prostate cancer	9.77e-05	0.000436	CcSEcCtD
Penicillamine—Hypersensitivity—Docetaxel—prostate cancer	9.73e-05	0.000434	CcSEcCtD
Penicillamine—Nausea—Etoposide—prostate cancer	9.44e-05	0.000421	CcSEcCtD
Penicillamine—Hypersensitivity—Capecitabine—prostate cancer	9.42e-05	0.00042	CcSEcCtD
Penicillamine—Anaemia—Doxorubicin—prostate cancer	9.33e-05	0.000416	CcSEcCtD
Penicillamine—Arthralgia—Epirubicin—prostate cancer	9.29e-05	0.000414	CcSEcCtD
Penicillamine—Agitation—Doxorubicin—prostate cancer	9.28e-05	0.000414	CcSEcCtD
Penicillamine—Anxiety—Epirubicin—prostate cancer	9.26e-05	0.000413	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	9.23e-05	0.000412	CcSEcCtD
Penicillamine—Urticaria—Prednisone—prostate cancer	9.05e-05	0.000404	CcSEcCtD
Penicillamine—Leukopenia—Doxorubicin—prostate cancer	9.04e-05	0.000403	CcSEcCtD
Penicillamine—Diarrhoea—Docetaxel—prostate cancer	9.04e-05	0.000403	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—MBTPS1—prostate cancer	9.01e-05	0.00627	CbGpPWpGaD
Penicillamine—Body temperature increased—Prednisone—prostate cancer	9e-05	0.000402	CcSEcCtD
Penicillamine—Diarrhoea—Capecitabine—prostate cancer	8.75e-05	0.00039	CcSEcCtD
Penicillamine—Thrombocytopenia—Epirubicin—prostate cancer	8.72e-05	0.000389	CcSEcCtD
Penicillamine—Skin disorder—Epirubicin—prostate cancer	8.65e-05	0.000386	CcSEcCtD
Penicillamine—Arthralgia—Doxorubicin—prostate cancer	8.6e-05	0.000383	CcSEcCtD
Penicillamine—Anxiety—Doxorubicin—prostate cancer	8.57e-05	0.000382	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—AMACR—prostate cancer	8.54e-05	0.00594	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SRD5A2—prostate cancer	8.54e-05	0.00594	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—DEGS1—prostate cancer	8.54e-05	0.00594	CbGpPWpGaD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.54e-05	0.000381	CcSEcCtD
Penicillamine—Anorexia—Epirubicin—prostate cancer	8.49e-05	0.000379	CcSEcCtD
Penicillamine—Vomiting—Docetaxel—prostate cancer	8.4e-05	0.000374	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisone—prostate cancer	8.39e-05	0.000374	CcSEcCtD
Penicillamine—Rash—Docetaxel—prostate cancer	8.33e-05	0.000371	CcSEcCtD
Penicillamine—Dermatitis—Docetaxel—prostate cancer	8.32e-05	0.000371	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HSD17B1—prostate cancer	8.15e-05	0.00567	CbGpPWpGaD
Penicillamine—Vomiting—Capecitabine—prostate cancer	8.13e-05	0.000363	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Epirubicin—prostate cancer	8.12e-05	0.000362	CcSEcCtD
Penicillamine—Thrombocytopenia—Doxorubicin—prostate cancer	8.07e-05	0.00036	CcSEcCtD
Penicillamine—Rash—Capecitabine—prostate cancer	8.06e-05	0.00036	CcSEcCtD
Penicillamine—Dermatitis—Capecitabine—prostate cancer	8.05e-05	0.000359	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	8.01e-05	0.00557	CbGpPWpGaD
Penicillamine—Skin disorder—Doxorubicin—prostate cancer	8.01e-05	0.000357	CcSEcCtD
Penicillamine—Anorexia—Doxorubicin—prostate cancer	7.86e-05	0.00035	CcSEcCtD
Penicillamine—Nausea—Docetaxel—prostate cancer	7.84e-05	0.00035	CcSEcCtD
Penicillamine—Diarrhoea—Prednisone—prostate cancer	7.79e-05	0.000348	CcSEcCtD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	7.75e-05	0.00539	CbGpPWpGaD
Penicillamine—Decreased appetite—Epirubicin—prostate cancer	7.74e-05	0.000345	CcSEcCtD
Penicillamine—Nausea—Capecitabine—prostate cancer	7.59e-05	0.000339	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	7.51e-05	0.000335	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HPGD—prostate cancer	7.26e-05	0.00505	CbGpPWpGaD
Penicillamine—Vomiting—Prednisone—prostate cancer	7.24e-05	0.000323	CcSEcCtD
Penicillamine—Rash—Prednisone—prostate cancer	7.18e-05	0.00032	CcSEcCtD
Penicillamine—Dermatitis—Prednisone—prostate cancer	7.17e-05	0.00032	CcSEcCtD
Penicillamine—Decreased appetite—Doxorubicin—prostate cancer	7.16e-05	0.00032	CcSEcCtD
Penicillamine—Urticaria—Epirubicin—prostate cancer	7.08e-05	0.000316	CcSEcCtD
Penicillamine—Body temperature increased—Epirubicin—prostate cancer	7.04e-05	0.000314	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	6.83e-05	0.00475	CbGpPWpGaD
Penicillamine—Nausea—Prednisone—prostate cancer	6.77e-05	0.000302	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	6.64e-05	0.00462	CbGpPWpGaD
Penicillamine—Hypersensitivity—Epirubicin—prostate cancer	6.56e-05	0.000293	CcSEcCtD
Penicillamine—Urticaria—Doxorubicin—prostate cancer	6.55e-05	0.000292	CcSEcCtD
Penicillamine—Body temperature increased—Doxorubicin—prostate cancer	6.52e-05	0.000291	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	6.47e-05	0.0045	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	6.31e-05	0.00439	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	6.17e-05	0.0043	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	6.17e-05	0.0043	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	6.15e-05	0.00428	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	6.15e-05	0.00428	CbGpPWpGaD
Penicillamine—Diarrhoea—Epirubicin—prostate cancer	6.09e-05	0.000272	CcSEcCtD
Penicillamine—Hypersensitivity—Doxorubicin—prostate cancer	6.07e-05	0.000271	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	5.84e-05	0.00406	CbGpPWpGaD
Penicillamine—Vomiting—Epirubicin—prostate cancer	5.66e-05	0.000253	CcSEcCtD
Penicillamine—Diarrhoea—Doxorubicin—prostate cancer	5.64e-05	0.000252	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism—HAO1—prostate cancer	5.63e-05	0.00392	CbGpPWpGaD
Penicillamine—Rash—Epirubicin—prostate cancer	5.62e-05	0.00025	CcSEcCtD
Penicillamine—Dermatitis—Epirubicin—prostate cancer	5.61e-05	0.00025	CcSEcCtD
Penicillamine—Nausea—Epirubicin—prostate cancer	5.29e-05	0.000236	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	5.25e-05	0.00365	CbGpPWpGaD
Penicillamine—Vomiting—Doxorubicin—prostate cancer	5.24e-05	0.000234	CcSEcCtD
Penicillamine—Rash—Doxorubicin—prostate cancer	5.2e-05	0.000232	CcSEcCtD
Penicillamine—Dermatitis—Doxorubicin—prostate cancer	5.19e-05	0.000232	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	5.03e-05	0.0035	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	4.99e-05	0.00347	CbGpPWpGaD
Penicillamine—Nausea—Doxorubicin—prostate cancer	4.9e-05	0.000218	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	4.84e-05	0.00337	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	4.68e-05	0.00326	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ABCG5—prostate cancer	4.61e-05	0.0032	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TST—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PSAT1—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CSAD—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GRHL1—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CBR1—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ADI1—prostate cancer	4.59e-05	0.00319	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	4.49e-05	0.00312	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	4.4e-05	0.00306	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CKMT2—prostate cancer	4.27e-05	0.00297	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GRHPR—prostate cancer	4.27e-05	0.00297	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—UGT2B15—prostate cancer	4.27e-05	0.00297	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—UGT2B17—prostate cancer	4.27e-05	0.00297	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	4.17e-05	0.0029	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—prostate cancer	4.1e-05	0.00285	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.07e-05	0.00283	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTM3—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AOX1—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PGAM2—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NAGLU—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SULT2B1—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MBTPS1—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—RFK—prostate cancer	4.01e-05	0.00279	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	3.92e-05	0.00273	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—GNG5—prostate cancer	3.87e-05	0.00269	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AMACR—prostate cancer	3.8e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP3A43—prostate cancer	3.8e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SRD5A2—prostate cancer	3.8e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—DEGS1—prostate cancer	3.8e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NAT1—prostate cancer	3.8e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	3.74e-05	0.0026	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	3.72e-05	0.00259	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HSD17B1—prostate cancer	3.63e-05	0.00252	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	3.63e-05	0.00252	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	3.49e-05	0.00243	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	3.47e-05	0.00241	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	3.43e-05	0.00239	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.3e-05	0.0023	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	3.27e-05	0.00228	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HPGD—prostate cancer	3.23e-05	0.00225	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—B4GALT4—prostate cancer	3.23e-05	0.00225	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.11e-05	0.00216	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TNFRSF21—prostate cancer	3.04e-05	0.00212	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	2.97e-05	0.00207	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MTAP—prostate cancer	2.96e-05	0.00206	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP7B1—prostate cancer	2.96e-05	0.00206	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.89e-05	0.00201	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SULT1E1—prostate cancer	2.88e-05	0.00201	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SRD5A1—prostate cancer	2.88e-05	0.00201	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.8e-05	0.00195	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.76e-05	0.00192	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HSD17B3—prostate cancer	2.75e-05	0.00191	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ACSL4—prostate cancer	2.75e-05	0.00191	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.72e-05	0.00189	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—UMPS—prostate cancer	2.64e-05	0.00183	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PHGDH—prostate cancer	2.64e-05	0.00183	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ARG2—prostate cancer	2.64e-05	0.00183	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.62e-05	0.00182	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.62e-05	0.00182	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—LDHB—prostate cancer	2.58e-05	0.0018	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP3A5—prostate cancer	2.54e-05	0.00177	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—RXRA—prostate cancer	2.49e-05	0.00174	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PDHA1—prostate cancer	2.45e-05	0.0017	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—UCP3—prostate cancer	2.45e-05	0.0017	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TCN2—prostate cancer	2.45e-05	0.0017	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTA3—prostate cancer	2.45e-05	0.0017	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HSD3B1—prostate cancer	2.34e-05	0.00163	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SLC22A3—prostate cancer	2.34e-05	0.00163	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—prostate cancer	2.27e-05	0.00158	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTA4—prostate cancer	2.24e-05	0.00156	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TBXAS1—prostate cancer	2.24e-05	0.00156	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	2.19e-05	0.00152	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTA2—prostate cancer	2.18e-05	0.00152	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SULT1A1—prostate cancer	2.16e-05	0.0015	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ABCG5—prostate cancer	2.16e-05	0.0015	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTA1—prostate cancer	2.11e-05	0.00147	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTO1—prostate cancer	2.08e-05	0.00145	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HSD3B2—prostate cancer	2.08e-05	0.00145	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NAT2—prostate cancer	2.08e-05	0.00145	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	2e-05	0.00139	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—LRP2—prostate cancer	2e-05	0.00139	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PLCB2—prostate cancer	2e-05	0.00139	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP2C18—prostate cancer	2e-05	0.00139	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—P4HB—prostate cancer	1.96e-05	0.00136	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SLC22A1—prostate cancer	1.91e-05	0.00133	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.91e-05	0.00133	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.88e-05	0.00131	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SULT2A1—prostate cancer	1.86e-05	0.00129	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MED12—prostate cancer	1.83e-05	0.00127	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GNG5—prostate cancer	1.81e-05	0.00126	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOA3—prostate cancer	1.75e-05	0.00121	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.72e-05	0.00119	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HPGDS—prostate cancer	1.67e-05	0.00116	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP2C19—prostate cancer	1.66e-05	0.00115	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ACHE—prostate cancer	1.62e-05	0.00112	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTT1—prostate cancer	1.62e-05	0.00112	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP2A6—prostate cancer	1.6e-05	0.00111	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.59e-05	0.00111	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AKR1C3—prostate cancer	1.55e-05	0.00108	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PRKACB—prostate cancer	1.55e-05	0.00108	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP17A1—prostate cancer	1.53e-05	0.00106	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.51e-05	0.00105	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.51e-05	0.00105	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOA2—prostate cancer	1.46e-05	0.00101	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SLC5A5—prostate cancer	1.39e-05	0.000967	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP2E1—prostate cancer	1.36e-05	0.000945	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NQO1—prostate cancer	1.34e-05	0.000934	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TH—prostate cancer	1.32e-05	0.000921	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.31e-05	0.000915	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP3A4—prostate cancer	1.31e-05	0.000911	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.3e-05	0.000906	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP1B1—prostate cancer	1.29e-05	0.000896	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GGT1—prostate cancer	1.25e-05	0.000867	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOA1—prostate cancer	1.23e-05	0.000854	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP19A1—prostate cancer	1.21e-05	0.000842	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—RXRA—prostate cancer	1.17e-05	0.000813	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.14e-05	0.00079	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—COMT—prostate cancer	1.13e-05	0.000783	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTP1—prostate cancer	1.12e-05	0.000779	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ITPR1—prostate cancer	1.1e-05	0.000767	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.08e-05	0.000754	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TYMS—prostate cancer	1.04e-05	0.000724	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTM1—prostate cancer	1.03e-05	0.000716	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—LPL—prostate cancer	1.01e-05	0.000703	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYP1A1—prostate cancer	9.76e-06	0.000679	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ERCC2—prostate cancer	9.68e-06	0.000673	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MTHFR—prostate cancer	9.09e-06	0.000633	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PPARA—prostate cancer	8.92e-06	0.000621	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CAV1—prostate cancer	8.39e-06	0.000584	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.01e-06	0.000558	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CG—prostate cancer	7.64e-06	0.000532	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—INS—prostate cancer	7.23e-06	0.000503	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CREBBP—prostate cancer	7.08e-06	0.000493	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CD—prostate cancer	6.72e-06	0.000467	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NOS3—prostate cancer	6.34e-06	0.000441	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CB—prostate cancer	5.86e-06	0.000407	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PTGS2—prostate cancer	5.8e-06	0.000404	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PTEN—prostate cancer	5.06e-06	0.000352	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—EP300—prostate cancer	4.83e-06	0.000336	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CA—prostate cancer	3.57e-06	0.000248	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AKT1—prostate cancer	2.92e-06	0.000203	CbGpPWpGaD
